Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02591's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.285 * Ranked among companies with meaningful Dividend Yield % only.
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co Dividend Yield % Chart
Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend
Dec23
Dec24
Dec25
Dividend Yield %
0.00
0.00
0.00
Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Dividend Yield %
0.00
0.00
0.00
0.00
0.00
HKSE:02591 vs VRTX, REGN, RVMD: Dividend Yield % Comparison
For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Innogen Pharmaceutical Group Co Dividend Yield % vs Biotechnology Industry
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a Dividend Yield % of 0.00% as of Aug. 08, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #999999 out of 150 companies in the Biotechnology industry.
Is Guangzhou Innogen Pharmaceutical Group Co's Dividend Yield % too high?
Guangzhou Innogen Pharmaceutical Group Co's current Dividend Yield % is 0.00%. Based on the distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #999999 out of 150 companies for Dividend Yield %. This places Guangzhou Innogen Pharmaceutical Group Co in the lower half of its industry. The industry median Dividend Yield % is 1.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.29, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Innogen Pharmaceutical Group Co's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current Dividend Yield % is 0.00% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score
Get the complete analysis for HKSE:02591
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02591 has been successfully added to your 
